Introduction
============

Coronary atherosclerotic heart disease, also known as coronary heart disease (CHD), is a very common cardiovascular disorder. It is one of the major causes leading to cardiac dysfunction in patients, and is the leading cause of death for both men and women worldwide ([@b1-etm-0-0-6264],[@b2-etm-0-0-6264]). It was recently reported that CHD incidence in developed countries has declined, while in developing countries has increased, which may be due to changes in diet as a result of economic development ([@b3-etm-0-0-6264]). High-fat diet and low cholesterol consumption play an important role in the pathogenesis of CHD ([@b4-etm-0-0-6264]). According to a WHO report published in 2011, the incidence of CHD in China was approximately 8%, and the mortality rate was the second in the world ([@b5-etm-0-0-6264]).

Cholesterol level is an important risk factor for patients with CHD, while the soluble thrombomodulin level can predict plaque stability in patients with CHD. Probucol demonstrated satisfactory therapeutic effects in protecting against atherosclerosis, stabilizing atherosclerotic plaques, preventing coronary artery restenosis, and lowering lipids ([@b6-etm-0-0-6264],[@b7-etm-0-0-6264]). Studies have shown that probucol was effective in the dissolution of atherosclerotic plaques, as well as the reduction of soluble thrombomodulin level, in patients with atherosclerosis ([@b8-etm-0-0-6264],[@b9-etm-0-0-6264]). In this study, 300 out of 583 patients with CHD who were admitted to Jining First People\'s Hospital (Jining, China) from February 2013 to February 2014 received conventional treatment, while the remaining 283 were treated with probucol in addition to the conventional treatment. A retrospective analysis was performed on the total cholesterol levels, atherosclerotic plaque sizes, and soluble thrombomodulin levels before and after treatment in both groups. The data were compared in order to explore the efficacy of probucol in CHD patients.

Patients and methods
====================

### Subjects

A total of 583 patients with CHD, admitted to Jining First People\'s Hospital (Jining, China) from February 2013 to February 2014, were recruited into this study. Their conditions were confirmed according to the diagnostic criteria for CHD published by WHO in 2012 ([@b10-etm-0-0-6264]). Of them, 300 patients received conventional treatment only, and were assigned to the control group. The remaining 283 patients were treated with probucol in addition to the conventional treatment, and were assigned to the observation group. Patients who also had the following conditions were excluded: unstable coronary artery disease, intermittent myocardial infarction, acute myocardial infarction, infectious disease, severe cardiac insufficiency, cancer, grade III hypertension, liver and kidney failure, and mental or learning disabilities. Patients who had incomplete clinical data were excluded as well. This study was approved by the Ethics Committee of Jining First People\'s Hospital (Jining, China), and patients or their families signed an informed consent.

### Methods

In conventional treatment, the following drugs were administered: antiplatelet agents, nitrate vasodilators, angiotensin-converting enzyme inhibitors, and α receptor blockers. For patients in the observation group, probucol was given at a dose of 500 mg twice a day for 16 weeks in addition to the conventional treatment. Probucol was manufactured by Qilu Pharmaceutical Co., Ltd. (Jinan, China) with SFDA approval no. H10980054.

### Observed indicators

Peripheral blood samples were collected, and atherosclerotic plaque images were obtained through ultrasound imaging. The total cholesterol level, atherosclerotic plaque area, and soluble thrombomodulin level were measured before treatment as well as 4, 8 and 16 weeks after treatment. The obtained data were compared between the two groups to determine the correlation of the total cholesterol and soluble thrombomodulin levels with atherosclerotic plaque area. Cholesterol test kits (DAOS method) and human soluble thrombomodulin (sTM) ELISA kits were purchased from Shanghai Yanhui Biotechnology Co., Ltd. (Shanghai, China) and Beijing BioDee Biotechnology Co., Ltd. (Beijing, China), respectively. The atherosclerotic plaque area was measured using a Philips iE33 color Doppler ultrasound system (Eindhoven, Netherlands).

### Statistical analysis

SPSS 19.0 statistics software from Asia Analytics (formerly SPSS China) was used for data processing. The χ^2^ test was applied in comparison of rates. Measurement data are expressed as mean ± standard deviation. The non-parametric K-S test was used for comparison between the two groups. A logistic association analysis was performed to estimate correlations of the atherosclerotic plaque area with the total cholesterol and soluble thrombomodulin levels. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical data

Of the 583 patients with CHD, 283 were assigned to the observation group, including 169 males and 114 females with an average age of 51.6±22.3 years. The remaining 300 patients were assigned to the control group, including 172 males and 128 females with an average age of 49.7±18.6 years. There were no significant differences in the basic data between the two groups such as sex, body weight, age, and number of coronary artery lesions (P\>0.05). Within the same group, the number of patients with multiple coronary artery lesions was higher than that of patients with single coronary artery lesion (P\<0.05), and the number of patients with weight ≥50 kg was greater than that of patients with weight \<50 kg (P\<0.05). Most patients in the two groups lived in urban areas (P\<0.05), and rarely had routine physical exercise (P\<0.05). The details are listed in [Table I](#tI-etm-0-0-6264){ref-type="table"}.

### Total cholesterol level after treatment

The total cholesterol level was monitored during treatment for all patients, which decreased gradually over time in both groups. After 4 weeks of treatment, small improvements in the total cholesterol level were observed in both groups (P\>0.05), but there was no difference between the two groups (P\>0.05). After 8 weeks of treatment, further improvements in the total cholesterol level were observed in both groups (P\<0.05), and the level in the observation group was much lower than that in the control group (P\<0.05). After 16 weeks of treatment, significant improvements in the total cholesterol level were observed in both groups (P\<0.05), whereas there was no significant difference between the two groups (P\>0.05). The data indicated that the conventional treatment in combination with probucol reduced the total cholesterol level of patients with CHD in a shorter time ([Table II](#tII-etm-0-0-6264){ref-type="table"}).

### Atherosclerotic plaque area after treatment

After 4 weeks of treatment, small decreases in plaque area were observed in both groups (P\>0.05), but there was no difference between the two groups. After 8 and 16 weeks of treatment, the plaque areas in the observation group were all significantly smaller than those in the control group (P\<0.05). Overall, the plaque area gradually decreased over time during treatment in both groups. After 8 and 16 weeks of treatment, the plaque area decreased significantly in the observation group (P\<0.05), whereas the plaque area decreased slightly at all time-points in the control group (P\>0.05). The data suggested that the conventional treatment in combination with probucol was much more effective in reducing plaque area than the conventional treatment only ([Table III](#tIII-etm-0-0-6264){ref-type="table"}).

### Soluble thrombomodulin level after treatment

Before treatment, there was no difference in soluble thrombomodulin level between the two groups (P\>0.05). Over time during treatment, the level decreased in both groups. The level at each time-point after treatment was significantly lower than that before treatment (P\<0.05). At the same time-point after treatment, the soluble thrombomodulin level in the observation group was much lower than that in the control group (P\<0.05). The data indicated that the conventional treatment in combination with probucol further reduced the soluble thrombomodulin level, compared with the conventional treatment only ([Table IV](#tIV-etm-0-0-6264){ref-type="table"}).

### Correlation analysis of atherosclerotic plaque area with total cholesterol and soluble thrombomodulin

Total cholesterol and soluble thrombomodulin levels were all positively correlated with the atherosclerotic plaque area (r=0.841, P=0.001; r=0.725, P=0.008).

Discussion
==========

CHD related morbidity and mortality are high worldwide, indicating CHD is a serious challenge to human health. Atherosclerosis is the leading cause of CHD. Reducing atherosclerotic plaque area, lowering cholesterol level in blood, and thinning the inner lining of coronary artery are important treatment strategies for improving the survival of CHD patients ([@b11-etm-0-0-6264],[@b12-etm-0-0-6264]). Soluble thrombomodulin is a biomarker of vascular endothelial damage. Lowering its level in blood can protect endothelial function and prevent thrombosis ([@b13-etm-0-0-6264]).

In this study, clinical data of 583 CHD patients treated from February 2013 to February 2014 were collected and retrospectively analyzed to explore the effects of probucol and the conventional treatment on atherosclerotic plaque and soluble thrombomodulin level. The results suggested that probucol promoted the shrinking of atherosclerotic plaque. After 8 weeks of treatment, patients in the observation group experienced significant plaque shrinkage (P\<0.05), whereas limited plaque shrinkage was observed in patients in the control group (P\>0.05). Our findings were in accordance with those reported in literature where Li *et al* reported that probucol alleviated progression of atherosclerotic lesion and the increase of plaque area by modulating NHE1 ([@b14-etm-0-0-6264]). Reducing the plaque area in a shorter time by administration of probucol in addition to the conventional treatment was important for the prevention of thrombosis in patients.

The total cholesterol level in blood was also monitored for all CHD patients. After 4 weeks of treatment, small improvements in the total cholesterol level were observed in both groups (P\>0.05). After 8 weeks of treatment, the level in the observation group was much lower than that in the control group (P\<0.05). Whereas after 16 weeks of treatment, the total cholesterol in both groups decreased to a comparable level, and there was no significant difference between them (P\>0.05). A faster reduction of the total cholesterol level by additional probucol administration may be beneficial to the atherosclerotic plaque shrinkage, because the total cholesterol level is an important risk factor for atherosclerosis ([@b15-etm-0-0-6264]). Correlation analysis also indicated that the total cholesterol level and atherosclerotic plaque area were positively correlated (r=0.841, P=0.001). Zhu *et al* reported that probucol effectively reduced plasma total cholesterol and high-density lipoprotein cholesterol levels, and alleviated atherosclerosis ([@b16-etm-0-0-6264]). Probucol was also reported to have a positive effect on stabilizing atherosclerotic plaque in patients with hypercholesterolemia ([@b17-etm-0-0-6264]).

In this study, the soluble thrombomodulin level in blood was measured as well. The level decreased in both groups over time during treatment. At the same time-point after treatment, the soluble thrombomodulin level in the observation group was much lower than that in the control group (P\<0.05). This indicated that additional probucol in the conventional treatment can improve the soluble thrombomodulin level more efficiently. Thrombomodulin is an endothelial cell surface glycoprotein that plays an important role in the vascular homeostasis. It is a determinant of thrombosis in the inner lining of blood vessels. Improving thrombomodulin level in blood was directly related to the alleviation of symptoms of patients with atherosclerosis, and played an important role in enhancing anticoagulation in patients and preventing thrombosis ([@b18-etm-0-0-6264],[@b19-etm-0-0-6264]). Correlation analysis in this study showed that a positive correlation between the plasma thrombomodulin level and atherosclerotic plaque area (r=0.725, P=0.008). This is consistent with the findings of Hong *et al* who reported that probucol reduced the soluble thrombomodulin level in blood, and may improve the endothelial function of rabbits with hypercholesterolemia ([@b20-etm-0-0-6264]).

Based on the findings in this study, probucol may exert its therapeutic effect on CHD by downregulation of the total cholesterol and thrombomodulin in blood, as well as reduction of the atherosclerotic plaque area. However, in this study, the collected patients\' data are not enough to completely analyze the incidence of complications in patients after using probucol, so it is limited to evaluate the safety of probucol. The preventive effects of probucol against atherosclerosis in patients with CHD have been previously reported. Yamashita *et al* ([@b21-etm-0-0-6264]) reported the safety of probucol in long-term treatment. However, in spite of these findings, we still aim to investigate this further.

In conclusion, when patients with CHD were treated with probucol in addition to the conventional treatment, a reduction of atherosclerotic plaque area, as well as a decrease of both the total cholesterol and soluble thrombomodulin levels, was observed. Overall, patients with CHD experienced improved symptoms following treatment with probucol.
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###### 

Basic clinical data of patients in the two groups.

  Items                                                      Control group   Observation group   t/χ^2^   P-value
  ---------------------------------------------------------- --------------- ------------------- -------- ---------
  No. of patients                                            300             283                          
  Sex                                                                                                     
    Male                                                     172             169                 0.762    0.519
    Female                                                   128             114                          
  Age (years)                                                49.7±18.6       51.6±22.3           0.547    0.744
  Coronary artery lesions (n, %)                                                                          
    Single                                                   91 (30.33)      100 (35.34)         0.594    0.625
    Multiple^[a](#tfn1-etm-0-0-6264){ref-type="table-fn"}^   209 (69.67)     183 (64.66)                  
  Body weight (kg), (n, %)                                                                                
    ≥50^[b](#tfn2-etm-0-0-6264){ref-type="table-fn"}^        214 (71.33)     182 (64.31)         0.175    0.969
    \<50                                                     86 (28.67)      101 (35.69)                  
  Residence area, (n, %)                                                                                  
    Urban^[c](#tfn3-etm-0-0-6264){ref-type="table-fn"}^      181 (60.33)     172 (60.78)         0.976    0.381
    Rural                                                    119 (39.67)     111 (39.22)                  
  Physical exercise, (n, %)                                                                               
    Yes                                                      103 (34.33)     102 (36.04)         1.147    0.311
    No^[d](#tfn4-etm-0-0-6264){ref-type="table-fn"}^         197 (65.67)     181 (63.96)                  

P=0.025 and 0.025, respectively, for comparison of the number of patients with multiple coronary artery lesions and the number of patients with single coronary artery lesion within the control and observation groups

P=0.013 and 0.031, respectively, for comparison of the number of patients with weight ≥50 kg and number of patients with weight \<50 kg within the control and observation groups

P=0.032 and 0.032, respectively, for comparison of the number of patients living in urban areas and the number of patients living in rural areas within the control and observation groups

P=0.029 and 0.030, respectively, for comparison of the number of patients with physical exercise habit and the number of patients without physical exercise habit within the control and observation groups.

###### 

Total cholesterol level after treatment (mmol/l).

  Time-points                 Control group                                                                                          Observation group                                         t       P-value
  --------------------------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------------- ------- ---------
  Before treatment            5.06±0.88                                                                                              5.13±0.97                                                 0.242   0.926
  After treatment, 4 weeks    4.31±0.39                                                                                              4.58±0.47                                                 0.413   0.843
  After treatment, 8 weeks    3.59±0.38^[a](#tfn5-etm-0-0-6264){ref-type="table-fn"}^                                                2.64±0.22^[d](#tfn8-etm-0-0-6264){ref-type="table-fn"}^   2.339   0.034
  After treatment, 16 weeks   2.56±0.24^[b](#tfn6-etm-0-0-6264){ref-type="table-fn"},[c](#tfn7-etm-0-0-6264){ref-type="table-fn"}^   2.33±0.17^[e](#tfn9-etm-0-0-6264){ref-type="table-fn"}^   0.641   0.672

P\<0.05, in comparison with the level before treatment

P\<0.05, in comparison with the level before treatment

P\<0.05, in comparison with the level 8 weeks after treatment

P\<0.05, in comparison with the level before treatment

P\<0.05, in comparison with the level before treatment.

###### 

Atherosclerotic plaque area after treatment (mm^2^).

  Time-points                 Control group   Observation group                                          t       P-value
  --------------------------- --------------- ---------------------------------------------------------- ------- ---------
  Before treatment            4.05±0.83       4.01±0.81                                                  0.213   0.943
  After treatment, 4 weeks    3.87±0.73       3.84±0.59                                                  0.147   0.985
  After treatment, 8 weeks    3.64±0.41       3.29±0.33^[a](#tfn10-etm-0-0-6264){ref-type="table-fn"}^   2.386   0.031
  After treatment, 16 weeks   3.62±0.45       3.15±0.28^[b](#tfn11-etm-0-0-6264){ref-type="table-fn"}^   2.426   0.029

P\<0.05, in comparison with the area before treatment

P\<0.05, in comparison with the area before treatment.

###### 

Soluble thrombomodulin level after treatment (µg/l).

  Time-points                 Control group                                              Observation group                                          t       P-value
  --------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ------- ---------
  Before treatment            68.7±25.6                                                  69.1±24.7                                                  0.294   0.914
  After treatment, 4 weeks    56.4±21.7^[a](#tfn12-etm-0-0-6264){ref-type="table-fn"}^   47.7±19.5^[d](#tfn15-etm-0-0-6264){ref-type="table-fn"}^   2.328   0.036
  After treatment, 8 weeks    48.1±18.9^[b](#tfn13-etm-0-0-6264){ref-type="table-fn"}^   34.5±16.8^[e](#tfn16-etm-0-0-6264){ref-type="table-fn"}^   2.349   0.032
  After treatment, 16 weeks   26.7±8.6^[c](#tfn14-etm-0-0-6264){ref-type="table-fn"}^    17.4±7.6^[f](#tfn17-etm-0-0-6264){ref-type="table-fn"}^    2.479   0.025

P\<0.05, in comparison with the level before treatment

P\<0.05, in comparison with the levels before treatment and 4 weeks after treatment

P\<0.05, in comparison with the levels before treatment and 8 weeks after treatment

P\<0.05, in comparison with the level before treatment

P\<0.05, in comparison with the levels before treatment and 4 weeks after treatment

P\<0.05, in comparison with the levels before treatment and 8 weeks after treatment.
